Caty Carrera Vargas1, Luis Solorzano1, Doris Guale1, Claudia Herrera2, Eric Dumonteil3. 1. Centro Nacional de Referencia de Parasitología, Instituto Nacional de Salud Publica, Guayaquil, Ecuador. 2. Department of Tropical Medicine and Vector-Borne and Infectious Disease Research Center, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, USA. 3. Department of Tropical Medicine and Vector-Borne and Infectious Disease Research Center, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, USA. edumonte@tulane.edu.
Abstract
PURPOSE: Chagas disease, caused by the protozoan parasite Trypanosoma cruzi, is a vector-borne disease with a major disease burden in the Americas, with over 6 million cases. There are about 200,000 cases in Ecuador, but the epidemiology of the disease is poorly understood, particularly in the Amazon region, making surveillance and control challenging. METHODS: We determined here the seroprevalence of T. cruzi antibodies in a cohort of 516 schoolchildren aged 5-15 years from Chontapunta parish, in the Napo province, Ecuador, using ELISA and indirect hemaglutination tests. RESULTS: We detected a seroprevalence of 0.77% (95% confidence interval 0.31-1.97%), with some significant variation among the three studied communities. CONCLUSION: These data provide evidence of the ongoing transmission of T. cruzi in this area, and support the need to strengthen epidemiological surveillance and patient care.
PURPOSE: Chagas disease, caused by the protozoan parasite Trypanosoma cruzi, is a vector-borne disease with a major disease burden in the Americas, with over 6 million cases. There are about 200,000 cases in Ecuador, but the epidemiology of the disease is poorly understood, particularly in the Amazon region, making surveillance and control challenging. METHODS: We determined here the seroprevalence of T. cruzi antibodies in a cohort of 516 schoolchildren aged 5-15 years from Chontapunta parish, in the Napo province, Ecuador, using ELISA and indirect hemaglutination tests. RESULTS: We detected a seroprevalence of 0.77% (95% confidence interval 0.31-1.97%), with some significant variation among the three studied communities. CONCLUSION: These data provide evidence of the ongoing transmission of T. cruzi in this area, and support the need to strengthen epidemiological surveillance and patient care.
Entities:
Keywords:
American trypanosomiasis; Chagas disease; Diagnostic; Pediatric; Seroprevalence
Authors: Carla L Black; Sofía Ocaña-Mayorga; Diana K Riner; Jaime A Costales; Mauricio S Lascano; Laura Arcos-Terán; John S Preisser; J Richard Seed; Mario J Grijalva Journal: Am J Trop Med Hyg Date: 2009-12 Impact factor: 2.345
Authors: Leonardo Quinde-Calderón; Paulina Rios-Quituizaca; Luis Solorzano; Eric Dumonteil Journal: Trop Med Int Health Date: 2015-11-09 Impact factor: 2.622
Authors: Eric Dumonteil; Claudia Herrera; Luiggi Martini; Mario J Grijalva; Angel G Guevara; Jaime A Costales; H Marcelo Aguilar; S Frédérique Brenière; Etienne Waleckx Journal: PLoS One Date: 2016-06-28 Impact factor: 3.240